Japan Compares World Drug Prices

2 October 1994

Prices of pharmaceuticals tend to be higher on average in Japan than in other major world markets, according to a survey conducted by the Japan Medical Practitioners' Federation and the Osaka Medical Practitioners' Association, reported in Pharma Japan.

A comparison of the National Health Insurance prices of the leading 29 branded drug products in Japan in 1993 showed in general higher prices on the domestic market than in the USA, the UK, germany and France, said the study. The price ratio in Japan compared to the USA was 1.54 for 25 of the brands, 2.94 compared to the UK for 24 brands, 1.44 for all 29 products against Germany, and 2.76 for 28 products compared to France.

Prices were found to be particularly high in Japan for recently-launched products, those developed overseas and those which were not highly evaluated in their countries of origin.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight